BRISTOL-MYERS SQUIBB COMPANY Repayments of Commercial Paper
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Repayments of Commercial Paper of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfCommercialPaper · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for the quarter ending 2025-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for the quarter ending 2024-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for the quarter ending 2024-09-30 was $269.00M.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for fiscal 2024 was $3.00B.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for fiscal 2023 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY repayments of commercial paper for fiscal 2022 was $0.00.
| Period end | Repayments of Commercial Paper 3 month | Repayments of Commercial Paper 6 month | Repayments of Commercial Paper 9 month | Repayments of Commercial Paper 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-07-31 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $269.00M derived: sum of 2 quarters · filed 2026-02-11 | $2.97B derived: sum of 3 quarters · filed 2026-02-11 | $3.00B 10-K · filed 2026-02-11 |
| 2024-09-30 | $269.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.97B derived: sum of 2 quarters · filed 2025-10-30 | $3.00B 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $2.70B 10-Q · filed 2024-07-26 | $2.73B 10-Q · filed 2025-07-31 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-07-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |